According to the pharmaceutical firm, the expansion resulted from the truth that the firm sent added info to the FDA in very early November as component of the application procedure.
发布者：BY Christopher Karlsson，转转请注明出处：https://robotalks.cn/fda-extends-review-period-for-ascendis-pharmas-dwarfism-drug/
